Effect of APOE and CHRNA7 Genotypes on the Cognitive Response to Cholinesterase Inhibitor Treatment at Different Stages of Alzheimer's Disease

Autor(es)

Sampaio Braga, Ianna Lacerda ^[1] ; Silva, Patricia Natalia ^[1] ; Furuya, Tatiane Katsue ^[1] ; Santos, Leonardo Caires ^[1] ; Pires, Belisa Caldana ^[1] ; Mazzotti, Diego Robles ^[1] ; Bertolucci, Paulo Henrique ^[2] ; Cendoroglo, Maysa Seabra ^[3] ; Smith, Marilia Cardoso ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo UNIFESP, Dept Morfol & Genet, Disciplina Genet, Sao Paulo, SP - Brazil

^[2] Univ Fed Sao Paulo, Dept Neurol & Neurocirurgia, Disciplina Neurol Clin, Sao Paulo, SP - Brazil

^[3] Univ Fed Sao Paulo, Dept Med, Disciplina Geriatria & Gerontol, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS; v. 30, n. 2, p. 139-144, MAR 2015.
• Citações Web of Science: 16

Resumo

The loss of cholinergic transmission is considered to be an important cause of Alzheimer's disease (AD). Treatment with acetyl cholinesterase inhibitors (ChEIs) shows benefits; however, great heterogeneity has been observed in patient responses. We evaluated apolipoprotein E (APOE) and 7 nicotinic receptor (CHRNA7) single-nucleotide polymorphisms (SNPs) and associated these SNPs with pharmacological responses to ChEIs in a Brazilian population with AD. We studied 177 outpatients using ChEIs, and they were classified as responders and nonresponders according to variation in Mini-Mental State Examination (MMSE) status. The analysis of APOE genotypes showed that patients with the 4 allele had a worse response than those without the 4 allele. We observed an association between the CHRNA7 T allele and a better response to treatment with ChEIs in patients with mild AD (MMSE 20). The SNP rs6494223 of CHRNA7 as well as APOE4 could be useful for understanding the response to ChEI treatment in patients with AD. (AU)